Literature DB >> 9596484

Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer.

S Roka1, M Fiegl, N Zojer, M Filipits, R Schuster, B Steiner, R Jakesz, H Huber, J Drach.   

Abstract

Previous work from our laboratory demonstrated aneuploidy for several chromosomes by interphase fluorescence in situ hybridization (FISH) in a high proportion of breast cancer specimens. In the literature, only limited data are available concerning chromosome 8 anomalies in breast cancer. To determine chromosome 8 ploidy status in primary and metastatic specimens from 81 breast cancer patients, FISH analysis with a DNA probe recognizing chromosome 8 centromeres was performed. In all primary tumor specimens (n = 30), significant proportions of cells were aneuploid exhibiting gain of chromosome 8 copy numbers; in 75% of effusion specimens previously classified as malignant by cytology and/or FISH for various chromosomes (n = 40), cell populations aneuploid for chromosome 8 were detected; effusions previously classified non-malignant (n = 11) were diploid in 10 cases, whereas one specimen contained rare hyperdiploid cells. Among these cells complex chromosomal aneuploidy could be demonstrated by two-color FISH, suggesting malignancy. Trisomic and tetrasomic clones were predominant in the majority of samples, but a marked intratumor cytogenetic heterogeneity was observed in most cases. Primary tumors and corresponding positive axillary lymph nodes revealed similar distributions of chromosome 8 copy numbers, analogous to previous findings with other chromosomes. This implies that, by using suitable FISH probes after examination of the respective primary tumor, an efficient search for (micro)metastasis might be feasible.

Entities:  

Mesh:

Year:  1998        PMID: 9596484     DOI: 10.1023/a:1005937305102

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  Monosomy of chromosome 8 could be considered as a primary preneoplastic event in breast cancer: A preliminary study.

Authors:  Fabiola A García Parra-Pérez; Angel Zavala-Pompa; Javier Pacheco-Calleros; Elva I Cortés-Gutiérrez; Ricardo M Cerda-Flores; Sandra Lara-Miranda; Martha I Dávila-Rodríguez
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

Review 3.  Insight into the heterogeneity of breast cancer through next-generation sequencing.

Authors:  Hege G Russnes; Nicholas Navin; James Hicks; Anne-Lise Borresen-Dale
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

4.  Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women: an interphase FISH analysis.

Authors:  Farkhondeh Behjati; Morteza Atri; Hossein Najmabadi; Keramat Nouri; Mahdi Zamani; Parvin Mehdipour
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

5.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

6.  Future medical applications of single-cell sequencing in cancer.

Authors:  Nicholas Navin; James Hicks
Journal:  Genome Med       Date:  2011-05-31       Impact factor: 11.117

Review 7.  Ductal approaches to assessment and management of women at high risk for developing breast cancer.

Authors:  Imogen Locke; Gillian Mitchell; Rosalind Eeles
Journal:  Breast Cancer Res       Date:  2004-01-26       Impact factor: 6.466

Review 8.  New concepts in breast cancer genomics and genetics.

Authors:  Rodrigo Goncalves; Wayne A Warner; Jingqin Luo; Matthew J Ellis
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

9.  Performance of the UroVysion® FISH assay for the diagnosis of malignant effusions using two cutoff strategies.

Authors:  Débora C B Rosolen; Daniel K Faria; Caroline S Faria; Leila Antonangelo
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.